201 related articles for article (PubMed ID: 19331859)
1. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors.
Hattori Y; Shi L; Ding W; Koga K; Kawano K; Hakoshima M; Maitani Y
J Control Release; 2009 May; 136(1):30-7. PubMed ID: 19331859
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
Kawato Y; Furuta T; Aonuma M; Yasuoka M; Yokokura T; Matsumoto K
Cancer Chemother Pharmacol; 1991; 28(3):192-8. PubMed ID: 1855276
[TBL] [Abstract][Full Text] [Related]
3. In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin.
Watanabe M; Kawano K; Toma K; Hattori Y; Maitani Y
J Control Release; 2008 May; 127(3):231-8. PubMed ID: 18384903
[TBL] [Abstract][Full Text] [Related]
4. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
5. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11.
Sadzuka Y; Hirotsu S; Hirota S
Cancer Lett; 1998 May; 127(1-2):99-106. PubMed ID: 9619864
[TBL] [Abstract][Full Text] [Related]
6. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
[TBL] [Abstract][Full Text] [Related]
7. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
Kumazawa E; Jimbo T; Ochi Y; Tohgo A
Cancer Chemother Pharmacol; 1998; 42(3):210-20. PubMed ID: 9685056
[TBL] [Abstract][Full Text] [Related]
8. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
Nakajima TE; Yanagihara K; Takigahira M; Yasunaga M; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Mihara K; Ochiya T; Matsumura Y
Cancer Res; 2008 Nov; 68(22):9318-22. PubMed ID: 19010905
[TBL] [Abstract][Full Text] [Related]
10. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.
Ramsay EC; Anantha M; Zastre J; Meijs M; Zonderhuis J; Strutt D; Webb MS; Waterhouse D; Bally MB
Clin Cancer Res; 2008 Feb; 14(4):1208-17. PubMed ID: 18281556
[TBL] [Abstract][Full Text] [Related]
11. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice.
Koshkina NV; Gilbert BE; Waldrep JC; Seryshev A; Knight V
Cancer Chemother Pharmacol; 1999; 44(3):187-92. PubMed ID: 10453719
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
Matsuzaki T; Takagi A; Furuta T; Ueno S; Kurita A; Nohara G; Kodaira H; Sawada S; Hashimoto S
Oncol Rep; 2012 Jan; 27(1):189-97. PubMed ID: 21935577
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
Nakajima TE; Yasunaga M; Kano Y; Koizumi F; Kato K; Hamaguchi T; Yamada Y; Shirao K; Shimada Y; Matsumura Y
Int J Cancer; 2008 May; 122(9):2148-53. PubMed ID: 18196580
[TBL] [Abstract][Full Text] [Related]
14. Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38.
Sadzuka Y; Hirotsu S; Hirota S
Jpn J Cancer Res; 1999 Feb; 90(2):226-32. PubMed ID: 10189894
[TBL] [Abstract][Full Text] [Related]
15. Liposomalization of SN-38 as active metabolite of CPT-11.
Sadzuka Y; Takabe H; Sonobe T
J Control Release; 2005 Nov; 108(2-3):453-9. PubMed ID: 16182400
[TBL] [Abstract][Full Text] [Related]
16. [Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative].
Furuta T; Yokokura T
Gan To Kagaku Ryoho; 1990 Jan; 17(1):121-30. PubMed ID: 2297233
[TBL] [Abstract][Full Text] [Related]
17. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
Messerer CL; Ramsay EC; Waterhouse D; Ng R; Simms EM; Harasym N; Tardi P; Mayer LD; Bally MB
Clin Cancer Res; 2004 Oct; 10(19):6638-49. PubMed ID: 15475454
[TBL] [Abstract][Full Text] [Related]
18. Preparation of irinotecan-loaded folate-targeted liposome for tumor targeting delivery and its antitumor activity.
Zhang Z; Yao J
AAPS PharmSciTech; 2012 Sep; 13(3):802-10. PubMed ID: 22639238
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
[TBL] [Abstract][Full Text] [Related]
20. Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study.
van Riel JM; van Groeningen CJ; Kedde MA; Gall H; Leisink JM; Gruia G; Pinedo HM; van der Vijgh WJ; Giaccone G
Clin Cancer Res; 2002 Feb; 8(2):405-12. PubMed ID: 11839656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
